Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07489651 · ClinicalTrials.gov registry record · Phase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
A Phase 2 study, sponsored by Reunion Neuroscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT07489651: Recruiting Phase 2 study, sponsored by Reunion Neuroscience.
NCT07489651 is a Phase 2 study that is actively recruiting participants, run by Reunion Neuroscience. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07489651, a Phase 2 study, is actively recruiting participants, sponsored by Reunion Neuroscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Primary Outcome
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety.
Interventions
- DRUG Placebo
- DRUG RE104 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT07489651 shows while recruiting
NCT07489651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07489651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07489651 about?
NCT07489651 is a clinical study titled "RE104 Safety and Efficacy Study in Generalized Anxiety Disorder". The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
What is the current status of trial NCT07489651?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2026-04-20. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07489651?
The interventions under investigation include: Placebo (DRUG), RE104 for Injection (DRUG).
Who is sponsoring clinical trial NCT07489651?
This trial is sponsored by Reunion Neuroscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07489651's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI